Tag: 177Lu-PSMA
-
Fast SPECT Acquisitions Enable Single-Time-Point Dosimetry for 177Lu-PSMA in mCRPC Patients
Overview Single-time-point (STP) dosimetry has emerged as a practical alternative to traditional multi-time-point approaches for radiopharmaceutical therapies. In metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177 labelled PSMA (177Lu-PSMA), STP dosimetry at around 48 hours post-administration can reliably estimate absorbed doses to kidneys and tumors, reducing imaging burden and streamlining clinical workflows. Why STP Dosimetry…
-
Fast SPECT Acquisitions Enable STP Dosimetry for 177Lu-PSMA in mCRPC
Overview Single time-point (STP) dosimetry is gaining traction in the management of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177 labeled PSMA (177Lu-PSMA). This approach aims to estimate absorbed radiation doses with a single post-therapy imaging session, typically around 48 hours, reducing imaging burden and resource use compared with traditional multi-time-point (MTP) dosimetry. Here we…
-
Fast SPECT acquisitions enable single-time-point dosimetry for 177Lu-PSMA in metastatic prostate cancer
Introduction Targeted radionuclide therapy with Lutetium-177 labelled PSMA (177Lu-PSMA) has emerged as a leading option for metastatic castration-resistant prostate cancer (mCRPC). Traditional dosimetry often relies on multiple time-point imaging to capture radiopharmaceutical pharmacokinetics, which can create a substantial imaging burden, workload, and costs. Single time-point (STP) dosimetry, particularly at about 48 hours post-administration, offers a…